Outcome of Board Meeting held on 25.10.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samsrita Labs reported zero revenue from operations for Q2 FY26 (ended September 30, 2025), with the company posting a standalone loss of Rs 493.50 lakhs for the quarter and Rs 521.16 lakhs for the half-year, sharply wider than Rs 13.20 lakhs loss in the same period last year. During the quarter, the company raised Rs 3.39 crores via preferential issue of 33.91 lakh shares and acquired a 28.625% stake in QROPS Advisory Services through a share swap of 45.50 lakh shares. It also purchased a cancer-treatment patent from Centre for Liver Research and Diagnostics (CLRD, a related party) for Rs 2 crores plus GST, settled via existing deposits. The company created a Rs 2.09 crore provision for doubtful debt from Mangal Savitri Bizcon and wrote off Rs 2.59 crore of advances with CLRD related to COVID-19 claims. The auditor (MGR & Co) issued an unqualified review report but flagged these matters under Emphasis of Matter.
For shareholders, this is a deeply negative quarter — zero revenue, ballooning losses, and a sharp jump in accumulated losses (negative reserves worsened from Rs 272.50 lakhs to Rs 793.66 lakhs in just six months). The stock may face pressure given the lack of operating business, though the company is attempting to pivot into healthcare/biotech via the patent acquisition and associate investments.